In principle, synergy is plausible in a few situations: Complementary pathways (e.g., appetite control + strength training adherence) Non-overlapping side-effect profiles Clear outcome tracking (so you can actually attribute effects) Where it tends to fall apart: Redundancy (two agents trying to push the same pathway) Hormonal axis pressure (especially GH/IGF-1 axis stacking) Long timelines with weak evidence (people run stacks for months because its peptides, not because outcomes justify it) For the rest of this article, Ill treat each stack as a clinical hypothesis and ask a simple question: If this were my patient, what would I be confident saying based on human evidenceand what would I label unknown? The 7 stacks people search for most (and what the evidence really supports) Quick comparison table Now, lets go stack by stack
Anything beyond 15% is increasingly transformative for mobility, energy, and disease risk reduction
The Lancet Psychiatry, 13, 327-335.
High-dose exogenous GH already elevates IGF-1 levels
Many women find peptide therapy helpful when traditional weight loss methods are no longer effective
Retrieved from Teixeira, C
